Notice2024-19040
AI-Enabled Medical Technologies Industry Roundtable
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 27, 2024
Issuing agencies
Commerce DepartmentInternational Trade Administration
Abstract
The International Trade Administration (ITA) of the Department of Commerce announces a roundtable discussion with industry representatives and U.S. government officials on strategies to increase U.S. industry competitiveness and support commercialization of U.S.- produced artificial intelligence (AI)-enabled medical technologies. ITA invites applications from industry representatives to participate in the roundtables. Applicants should be existing producers/providers or prospective new market entrants in the AI-enabled medical technology sector with solutions that are or will be produced or developed in the United States and exported overseas.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 166 (Tuesday, August 27, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 166 (Tuesday, August 27, 2024)]
[Notices]
[Page 68584]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-19040]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
International Trade Administration
AI-Enabled Medical Technologies Industry Roundtable
AGENCY: International Trade Administration, Department of Commerce.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The International Trade Administration (ITA) of the Department
of Commerce announces a roundtable discussion with industry
representatives and U.S. government officials on strategies to increase
U.S. industry competitiveness and support commercialization of U.S.-
produced artificial intelligence (AI)-enabled medical technologies. ITA
invites applications from industry representatives to participate in
the roundtables. Applicants should be existing producers/providers or
prospective new market entrants in the AI-enabled medical technology
sector with solutions that are or will be produced or developed in the
United States and exported overseas.
DATES:
Event: The roundtable will be held on Wednesday, October 30, 2024,
from 2:30 p.m. to 4:30 p.m., Eastern Daylight Time.
Event Registration: ITA will evaluate registrations based on the
submitted information (see below) and inform applicants of selection
decisions, which will be made on a rolling basis until a maximum of 20
participants have been selected.
ADDRESSES:
Event: The roundtable will be held via Microsoft Teams, and the
link for the meeting will be provided to selected and registered
participants.
FOR FURTHER INFORMATION CONTACT: Liam Kraft at 771-216-4432 or via
email at <a href="/cdn-cgi/l/email-protection#78301d19140c103931380c0a191c1d561f170e"><span class="__cf_email__" data-cfemail="4f072a2e233b270e060f3b3d2e2b2a61282039">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: AI is anticipated to yield significant
growth opportunities for the healthcare sector. With AI regulation and
policy formation still nascent in many markets, it is important to
understand the implications of changes in these areas for U.S.
healthcare industry stakeholders as governments, practitioners, and
patients increasingly adopt AI solutions in healthcare and as demand
for AI-enabled medical technologies grows in overseas markets. This
discussion will help position ITA to work with U.S. industry
stakeholders in ways that can enhance U.S. industry competitiveness in
overseas markets and reduce current or future trade barriers faced by
companies in this space.
The Department seeks individual input and views at the 10/30/2024
roundtable regarding overseas competitiveness of U.S. companies
producing, or planning to produce, and exporting AI-enabled medical
technologies. Participants will be encouraged to provide any relevant
feedback on this issue during the roundtable, which may include
comments on the following non-exhaustive list of possible topics:
<bullet> With the introduction of technologies such as foundational
models and general-purpose AI, what are the implications of regulatory
and policy shifts in markets to which your company exports AI-enabled
medical technologies, and how have these changes affected your
company's competitiveness?
<bullet> Which markets, given shifting regulatory and policy
landscapes, present the most conducive environment for the
competitiveness of U.S. AI-enabled medical technologies, from your
experience?
<bullet> How do you assess the potential for public-private
partnerships (P3s) to support efforts in the healthcare sector to
deliver AI-enabled medical technologies to overseas markets? What would
a successful P3 in this space look like? What kind of resources are
needed from the U.S. Government to enable this success?
<bullet> What kinds of strategic international engagements do you
believe would be most effective in supporting U.S. providers of AI-
enabled medical technologies and their competitiveness in overseas
markets?
<bullet> What kinds of trade barriers are you seeing negatively
affect U.S. competitiveness for AI-enabled medical technologies in
overseas markets? Where do you encounter these barriers? How do you
think the barriers can be reduced, removed, or prevented?
[cir] What are the implications of regulations/policies around
health data in foreign markets for U.S. competitiveness in AI-enabled
medical technologies that you're seeing in your work?
The event is closed to press and the public. Industry participation
is limited to a maximum of 20 qualifying industry representatives.
Selection
To attend, participants should submit the below information to
<a href="/cdn-cgi/l/email-protection#da92bfbbb6aeb29b939aaea8bbbebff4bdb5ac"><span class="__cf_email__" data-cfemail="c189a4a0adb5a9808881b5b3a0a5a4efa6aeb7">[email protected]</span></a> by no later than 10/23/2024. ITA will evaluate
registrations based on the submitted information (and based on the
criteria below) on a rolling basis until a maximum of 20 participants
have been selected and inform applicants of selection decisions.
Applicants are encouraged to send representatives at a sufficiently
senior level to be knowledgeable about their company's capabilities,
interests, and challenges in the global market of AI-enabled medical
technologies. Due to time constraints, there is a limit of one person
to speak on behalf of each company.
Applicants should include the following information in their
response email:
<bullet> Name of attendee and short bio.
<bullet> Name of company and brief company description.
<bullet> A statement self-certifying how the company meets each of
the following criteria:
1. It is not majority owned by a foreign government entity (or
entities).
2. It is an existing provider or prospective new market entrant, of
AI-enabled medical technologies that are or will be produced in the
United States in one or more of the following segments: Machine
learning, natural language processing, clinical, disease detection,
medical imaging, personalized care, patient monitoring, robotics, or
healthcare administration.
3. The representative will be able to attend the entire roundtable.
Selection will be based on the following criteria:
<bullet> The company's production or production plans with respect
to AI-enabled medical technologies.
<bullet> The company's experience in exporting AI-enabled medical
technologies from the United States to overseas markets.
<bullet> Suitability of the representative's position and biography
to be able to engage in the conversation.
<bullet> Ability of the company to contribute to the roundtable's
purpose of seeking individual input and views on policies and
initiatives that strengthen U.S. industry competitiveness of U.S.
exports.
Dated: August 20, 2024.
Amanda Lawrence,
Acting Director, Office of Health Industries, International Trade
Administration.
[FR Doc. 2024-19040 Filed 8-26-24; 8:45 am]
BILLING CODE 3510-DR-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 27, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.